Current Status of the Spectrum and Therapeutics of <i>Helicobacter pylori</i>-Negative Mucosa-Associated Lymphoid Tissue Lymphoma by Sung-Hsin Kuo, Kun-Huei Yeh, Chung-Wu Lin, Jyh-Ming Liou, Ming-Shiang Wu, Li-Tzong Chen, Ann-Lii Cheng

“…For antibiotic-unresponsive HP-negative MALT lymphoma, high-dose macrolides and immunomodulatory drugs, such as thalidomide and lenalidomide, have reported sporadic success. …”
Get full text

Chronic Active Epstein-Barr Virus Infection With Systemic Vasculitis and Pulmonary Arterial Hypertension in a Child by Hongjun Ba, Lingling Xu, Huimin Peng, Yuese Lin, Xuandi Li, Huishen Wang, Youzhen Qin

“…He was again started on prednisone, with an addition of thalidomide. Sildenafil was replaced by riociguat, due to the side effect of penile erection. …”
Get full text

The revolution in frontline treatment of Multiple Myeloma by Clauido Cerchione

“…The frontline treatment of multiple myeloma has recently been revolutioned, thanks to the approval of a new backbone, daratumumab, anti-CD38 monoclonal antibody, in both transplant-eligibile and -not eligibile patients.In transplant-eligible setting, daratumumab has been added, according to CASSIOPEIA trial, to the previous standard-of-care bortezomib-thalidomide-dexamethasone (Dara-VTD), followed by autologous-stem cell transplantation (ASCT), two cycles of consolidation, and oral lenalidomide maintenance until progression.In transplant-ineligible setting, daratumumab is added, according to MAIA trial, to lenalidomide-dexamethasone (DRD) until progression, or, according to ALCYONE Trial, to bortezomib-melphalan-prednisone (Dara-VMP) x 9 cycles.Results are incredible in both settings in terms of efficacy and tolerability, with the achievement of very good quality of life for patients, also thanks to the schedules and the subcutaneous administration of daratumumab.Achieving the deepest response correlates with the best long term result, and that's why, in this scenario, the endpoint becomes not only the achievement of complete response/stringent complete response, but also MRD negativity. …”
Get full text

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China by Wenjiao Tang, Jinrong Yang, Yan Li, Li Zhang, He Li, Jie Wang, Yi Liao, Chunlan Zhang, Ying Qu, Yuhuan Zheng, Ting Niu

“…The Cox proportional hazards regression model was applied to analyze the risk factors of frontline treatment attrition.Results: A total of 1,255 newly diagnosed MM were enrolled, with 573 (45.7%) patients receiving only one LOT and 682 (54.3%) patients receiving more than one LOT. Thalidomide with dexamethasone/prednisone was the most common frontline treatment before 2017, while bortezomib-based regimens constituted the majority of frontline treatment in 2017 and beyond. …”
Get full text

Treatment of multiple myeloma at Clinical Department of Hematology, University Medical Centre Ljubljana with autologous hematopoietic stem cell transplantation in years 2014 and 20... by Samo Zver, Enver Melkić, Tanja Radevska

“…Induction treatment at the time of diagnosis consisted of: VD (bortezomib, dexamethasone) 60/73 patients (82%), VCD (bortezomib, cyclophosphamide, dexamethasone)  10/73  patients (14%) and VTD (bortezomib, thalidomide, dexamethasone) 3/73 (5%)  patients. As part of induction therapy, patients received from 1 to 9 cycles of treatment. …”
Get full text

Caprine pancreatic islet xenotransplantation into diabetic immunosuppressed BALB/c mice by Hani, Homayoun, Allaudin, Zeenathul Nazariah, Mohd Lila, Mohd Azmi, Tengku Ibrahim, Tengku Azmi, Othman, Abas Mazni

“…Caprine islets (2000 islet equivalent) were transplanted beneath the kidney capsules of diabetic BALB/c mice under thalidomide-induced immunosuppression. Blood glucose and insulin levels of grafted mice were evaluated by glucometer and enzyme-linked immunosorbent assay kit, respectively. …”
Get full text

Drug-Coated Balloons: Drugs Beyond Paclitaxel? by Tobias Haase, Ulrich Speck, Stephanie Bienek, Melanie Löchel, Nadia Brunacci, Ole Gemeinhardt, Denise Schütt, Stephanie Bettink, Bettina Kelsch, Bruno Scheller, Beatrix Schnorr

“…Angiographic parameters such as late lumen loss (LLL) at 4 weeks did not show reduction of in-stent neointimal proliferation by treatment with arsenic trioxide (0.87 ± 0.44 mm), betamethasone dipropionate (1.00 ± 0.54 mm), bortezomib (1.74 ± 0.46 mm), green tea extract (1.24 ± 0.51 mm), fantolon, an epothilone (0.86 ± 0.61 mm), methotrexate (1.09 ± 0.72 mm), and thalidomide (1.59 ± 0.55 mm) compared to treatment with uncoated balloons (1.07 ± 0.60 mm), while coatings with paclitaxel reliably reduced in-stent stenosis (LLL = 0.36 ± 0.25 mm). …”
Get full text

Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review by Isti Rahayu Suryani, Isti Rahayu Suryani, Iraj Ahmadzai, Minh Ton That, Sohaib Shujaat, Sohaib Shujaat, Reinhilde Jacobs, Reinhilde Jacobs

“…Patients administered with bisphosphonates, steroids, chemotherapy, thalidomide, interferon, and hormone therapy had a significantly higher association between decreased salivary flow and MRONJ occurrence. …”
Get full text

Hematologists’ awareness of venous thromboembolism in multiple myeloma: a national survey in China by Qun Li, Bo Zhang, Qianwen Cheng, Fei Zhao, Junying Li, Han Yan, Aoshuang Xu, Chunyan Sun, Yu Hu

“…Most hematologists could select appropriate thromboprophylaxis for common anti-MM regimens such as VCd (bortezomib, cyclophosphamide, and dexamethasone) and VRd (bortezomib, lenalidomide, and dexamethasone), but not for uncommon ones such as VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) and KRd (carfilzomib, lenalidomide, and dexamethasone). …”
Get full text

Chiral Resolution, Absolute Configuration Assignment, and Genotoxicity Evaluation of Racemic 3,4-Dihydroquinazoline as a Novel Anticancer Agent by Junseong Ahn, Dohyeong Ko, Seyoung Yang, Kwang H. Moon, Jiwon Woo, Ho Yoo, Joohoon Ahn, Jeong H. Lee, Kyung S. Chung, Kyung-T. Lee, Jae Y. Lee

“…If a new drug candidate will be a mixture of enantiomers, both enantiomers should be separately studied for at least latent genotoxicity as early as possible since the thalidomide tragedy. Our group has recently reported that KCP-10043F (OZ-001) as a racemate (±)-3,4-dihydroquinazoline derivative strongly represses the proliferation of human A549 lung cancer cells by caspase-mediated apoptosis via STAT3 inactivation. …”
Get full text

Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based the... by Heinz Ludwig, Bela Hausmann, Martin Schreder, Wolfram Pönisch, Niklas Zojer, Stefan Knop, Eberhard Gunsilius, Alexander Egle, Andreas Petzer, Hermann Einsele, Roman Hajek, Katja Weisel, Karl Jochen Krenosz, Alois Lang, Daniel Lechner, Richard Greil, David Berry

“…Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression‐free survival (PFS) (10.2 vs 8.5 months, P = .04), particularly in patients with very long (>75% quartile) PFS . …”
Get full text

Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib by Wei Wang, Wei Wang, Siming Peng, Sihao Gao, Meiying Quan, Lijuan Gou, Changyan Wang, Zhixing Sun, Zhuo Li, Dongmei Lian, Hongmei Song

“…He was treated with ruxolitinib accompanied by steroids and thalidomide for about four years. The rash, hematological manifestations, and the liver function were all improved, but the erythrocyte sedimentation rate remained consistently elevated until the addition of tocilizumab, a monoclonal antibody against interleukin 6. …”
Get full text

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications by Haotian Shi, Wei Wei, Rong Peng, Haimin Chen, Nian Zhou, Lixia Wu, Wenjun Yu, Wenhao Zhao, Jian Hou, Fan Zhou

“…Background/objectiveWe retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications.MethodsA total of 130 RRMM patients with severe complications were enrolled in this study, among which 41 patients were further given bortezomib, lenalidomide, thalidomide or ixazomib on the basis of CP regimen (CP+X group). …”
Get full text

Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospec... by Deyu Li, Zhangzhou Huang, Jiangming Zhong, Li Lin, Guifeng Zhang, Wu Zhuang, Zhenhua Liu

“…Those who had prior treatment with any PARP inhibitor or antiangiogenic agent includes anlotinib, bevacizumab, sorafenib, and thalidomide are excluded. Eligible patients will receive oral anlotinib 8 mg once daily and oral fluzoparib 150 mg twice daily until disease progression or intolerable toxicity. …”
Get full text

Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol by Camille Winnicki, Pierre Leblond, Franck Bourdeaut, Anne Pagnier, Gilles Paluenzela, Pascal Chastagner, Gwenaelle Duhil-De Benaze, Victoria Min, Hélène Sudour-Bonnange, Catherine Piette, Natacha Entz-Werle, Sylvie Chabaud, Nicolas André

“…Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and intraventricular chemotherapy. …”
Get full text

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia by Qerimi V, Kapedanovska Nestorovska A, Sterjev Z, Genadieva-Stavric S, Suturkova L

“…Cyril and Methodius University in Skopje, Skopje, Macedonia; 2Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT &ndash; University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria; 3Medical Faculty, University Hematology Clinic, Skopje, Macedonia Purpose: A decision-analytic model was developed to study the impact of induction regimens vincristine, adriamycin, dexamethasone (VAD); thalidomide, dexamethasone (TD); and bortezomib, dexamethasone (BorD), followed by autologous stem cell transplantation (ASCT) for treating multiple myeloma (MM) patients in Macedonia. …”
Get full text

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) by Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala

“…Similarly, Patient 2, refractory to frontline bortezomib-thalidomide-dexamethasone therapy, attained CR following a transition to bortezomib-dexamethason-venetoclax treatment. …”
Get full text

The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma by Karolina Łuczkowska, Magdalena Rutka, Dorota Rogińska, Edyta Paczkowska, Bartłomiej Baumert, Sławomir Milczarek, Martyna Górska, Piotr Kulig, Bogumiła Osękowska, Michał Janowski, Krzysztof Safranow, Krzysztof Sommerfeld, Ewa Borowiecka, Piotr Zawodny, Anna Koclęga, Grzegorz Helbig, Bogusław Machaliński

“…In the present study, we aimed to assess the potential relationship between proinflammatory factors and the development of PN in MM patients with particular emphasis on the application of VTD (bortezomib, thalidomide, dexamethasone) regimen. Our analysis identified increased concentrations of CCL2, IL-1β, and IFN-γ in plasma of MM patients during treatment, both with and without symptoms of PN, compared with untreated neuropathy-free MM patients. …”
Get full text

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study by Maria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, Enrico Orciuolo, Francesco Ghio, Sara Ciofini, Veronica Candi, Giulia Fontanelli, Irene Attucci, Giuseppe Formica, Monica Bocchia, Sara Galimberti, Mario Petrini, Gabriele Buda

“…POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. …”
Get full text

Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells by Thamir M. Ismail, Rachel G. Crick, Min Du, Uma Shivkumar, Andrew Carnell, Roger Barraclough, Guozheng Wang, Zhenxing Cheng, Weiping Yu, Angela Platt-Higgins, Gemma Nixon, Philip S. Rudland

“…The moderately-weak S100A4-inhibitory compound, US-10113 has been chemically attached to thalidomide to stimulate the proteasomal machinery of a cell. …”
Get full text